Evidence map›Paper›PMID 41606422›Full record

ArticleJournal of cellular and molecular medicine2026

Effects of Periodontal-Specific Exosomes and rhBMP2 on Osteogenic Behaviour and Differentiation of BMSCs.

Paras Ahmad, Danyal A Siddiqui, Jared Bianchi-Smak, Nima Farshidfar, Nathan Estrin, Richard J Miron, Georgios A Kotsakis

Abstract read
In one paragraph

Article in Journal of cellular and molecular medicine, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 4 papers.

0numbers the graph read from it
0cells of the map it votes in
4citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

4 citing papers in PubMed.

  1. Article
  2. Article
  3. Review
  4. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

7 authors.

Paras AhmadDepartment of Oral Biology, Rutgers School of Dental Medicine, The State University of New Jersey, Newark, New Jersey, USA.ORCID https://orcid.org/0000-0001-7306-9795
Danyal A SiddiquiDepartment of Oral Biology, Rutgers School of Dental Medicine, The State University of New Jersey, Newark, New Jersey, USA.ORCID https://orcid.org/0000-0002-2398-5979
Jared Bianchi-SmakDepartment of Biological Sciences, Rutgers University, Newark, New Jersey, USA.
Nima FarshidfarDepartment of Periodontology, University of Bern, Bern, Switzerland.ORCID https://orcid.org/0000-0003-2944-5305
Nathan EstrinDepartment of Periodontology, Lake Erie College of Osteopathic Medicine School of Dental Medicine, Bradenton, Florida, USA.ORCID https://orcid.org/0000-0001-5780-3777
Richard J MironDepartment of Periodontology, University of Bern, Bern, Switzerland.ORCID https://orcid.org/0000-0003-3290-3418
Georgios A KotsakisDepartment of Oral Biology, Rutgers School of Dental Medicine, The State University of New Jersey, Newark, New Jersey, USA.

Funding

Miron Research and Development in Dentistry
6 · The paper itself

Abstract

Growth factors, including recombinant human bone morphogenetic protein-2 (rhBMP2), have been clinically utilised for large bone augmentation with good outcomes. Nevertheless, long-term healing, swelling, safety concerns, and high cost limit their use. Exosomes, nanoscale extracellular vesicles, have emerged as promising regenerative alternatives. This study assessed the osteogenic potential of periodontal-specific exosomes (Px) on bone marrow mesenchymal stem cells (BMSCs) compared to rhBMP2. Px were morphologically characterised by TEM and quantified via BCA assay. BMSCs were treated with Px at 1:10, 1:50, and 1:100 dilutions (100, 20, and 10 μg/mL) and compared to rhBMP2 (100 ng/mL). Px uptake was evaluated using PKH26 labeling. Functional assays included viability, migration, alkaline phosphatase (ALP) activity, alizarin red (ARS) mineralization, collagen, osteocalcin secretion, and RT-PCR analysis of osteogenic genes. Px exhibited spheroidal to cup-shaped morphology and internalisation in BMSCs up to 18 days. Compared to rhBMP2, Px promoted viability (1.14-fold), migration (1.78-fold) up to 1.14 and 1.78-fold, ALP (1.48-, 4.11-fold), ARS (1.43-, 14.71-fold), collagen (1.40-, 3.58-fold), and osteocalcin (1.86-, 5.2-fold). Gene expression demonstrated significant upregulation of ALP (1.73-fold), RUNX2 (1.70-fold), OCN (1.36-fold), and OPN (1.35-fold). Overall, Px significantly enhanced BMSC osteogenesis compared to rhBMP2, highlighting their potential as a cell-free nanotherapeutic in bone tissue engineering.

Indexed as

Bone Marrow CellsBone Morphogenetic Protein 2Cell DifferentiationExosomesMesenchymal Stem CellsOsteogenesisAlkaline PhosphataseCalcification, PhysiologicCell MovementCells, CulturedCell SurvivalCollagenGene Expression RegulationHumansOsteocalcinRecombinant ProteinsAlkaline PhosphataseBMP2 protein, humanBone Morphogenetic Protein 2CollagenOsteocalcinRecombinant Proteinsamniotic fluidbone marrow cellsbone morphogenetic protein 2exosomesmesenchymal stem cells

Identifiers

PMID41606422
PMCPMC12852057

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.